MindRank Announces First-in-Class Candidate MRANK-106 Enters IND-Enabling Stage for Multiple Hard-to-Treat Cancers
MindRank
AI Drug Developer
On November 6, 2023, MindRank, which focuses on using AI-driven new drug research and development, announced that it is targeting"First-in-Class" Anticancer Drug Project Targeting DNA Damage Repair Checkpoints and Synergistic High-Expression Targets in Pancreatic Cancer, Esophageal Cancer, and Hematological DiseasesMindRank-106 Successfully Completes Preclinical Candidate Compound (PCC) Confirmation,Obtained for pancreatic cancer, esophageal cancer, T-cell lymphoma, triple-negative breast cancer and other cancers that currently have no effective treatment methods.A candidate molecule with significant single-agent efficacy and superior combination synergy has officially entered the IND-Enabling study phase.
MRANK-106 is the third PCC molecule nominated by MindRank under the assistance of its one-stop AI drug discovery platform Molecule Pro, and also the first officially nominated "First-in-Class" project candidate molecule. The company's self-developed knowledge graph platform PharmKG assisted the biology team in selecting/discovering the innovative mechanism target combination, while the medicinal chemistry team fully utilized the multi-objective optimization function of the Molecule Pro platform to efficiently discover MRANK-106, a first-in-class PCC candidate molecule.
Preclinical studies have shown that this potent multi-target synergistic oral candidate drug molecule overcomes the shortcomings of weak efficacy and narrow safety windows associated with previous drugs targeting single DNA damage repair mechanisms or single highly expressed cancer targets. It has demonstrated promising results in multiple animal models of cancer, including pancreatic cancer, esophageal cancer, T-cell lymphoma, triple-negative breast cancer, and colorectal cancer.Potent anti-tumor activity, with good pharmacokinetics and safety.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby helping more lives regain health.
MindRank's AI pharmaceutical solutions were rated by the authoritative European and American institution Deep Pharma Intelligence as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020." In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list.
For more information, please visit the website: www.mindrank.ai
Other: info@mindrank.ai
